ArticleJournal of leukocyte biology2025
Human CD24+CD38+ regulatory B cells promote pro-resolving macrophage function through the synergistic effect of IL-10 and PD-L1.
Article in Journal of leukocyte biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CD24 as an innate immune checkpoint in solid tumors: biology, biomarker stratification, and therapeutic translation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Regulatory B cells, specifically the CD24+CD38+ phenotype, are known for their capacity to reduce inflammation by releasing interleukin 10. However, their potential role in regulating inflammation through macrophage differentiation is not well understood. This study investigates how CD24+CD38+ regulatory B cells modulate the differentiation and function of pro-resolving macrophages through programmed death-ligand 1/programmed death-1 interactions and interleukin 10 secretion. Human CD24+CD38+ B cells were isolated from peripheral blood and co-cultured with THP-1-derived macrophages. Recombinant interleukin 10/ programmed death-ligand 1 and neutralizing antibodies were used to conduct gain and loss-of-function studies. Flow cytometry, quantitative PCR, and mass spectrometry were used to evaluate macrophage polarization, efferocytosis activity, and pro-resolving lipid mediator production. After co-culture, M2 polarization, programmed death-1 expression, and efferocytosis activity were increased significantly. Inhibition of either interleukin 10 or programmed death-ligand 1 pathway reduced M2 macrophage differentiation and functional activity. Co-culture of macrophages with CD24+CD38+ B cells enhanced the production of pro-resolving lipid mediators, particularly 12-HEPE and RvD5 through interleukin 10 secretion and programmed death-ligand 1/programmed death-1 ligation. These findings reveal a novel mechanism by which human CD24+CD38+ regulatory B cells promote macrophage-mediated resolution of inflammation through interleukin 10 secretion and programmed death-ligand 1/programmed death-1 ligation. By exploring how these regulatory pathways influence macrophage biology, we ultimately aim to uncover novel therapeutic targets for enhancing inflammation resolution in chronic inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.